Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study

Daniel D. von Hoff, Thomas R. Fleming, John S. Macdonald, Phyllis J. Goodman, John Van Damme, Thomas D. Brown, Timothy O'Rourke, Lynn G. Feun, Michael D. Keppen

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)584-587
Number of pages4
JournalJournal of Biological Response Modifiers
Volume9
Issue number6
StatePublished - Dec 1990

Keywords

  • γ-Interferon
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this

    von Hoff, D. D., Fleming, T. R., Macdonald, J. S., Goodman, P. J., Damme, J. V., Brown, T. D., O'Rourke, T., Feun, L. G., & Keppen, M. D. (1990). Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study. Journal of Biological Response Modifiers, 9(6), 584-587.